Announcement

Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC, has closed its merger with Flex Pharma, Inc.’s wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc. The newly combined company will focus on the continued development of Salarius’ clinical pipeline, which targets rare, orphan cancers for which no approved targeted treatments are currently available and cancers with a high unmet need. The company will be led by Salarius’ current management team under the leadership of President and CEO, David Arthur. Former Flex Pharma President and CEO, William McVicar, Ph.D., will join Salarius’ Board of Directors. The company’s common stock will trade on the Nasdaq Capital Market under the new ticker symbol “SLRX” beginning on July 22, 2019 and will reflect the previously announced 25:1 reverse stock split that occurred effective as of the close of business on July 19, 2019.

PharmaJet and Mundipharma partner to expand access to needle-free technology in emerging markets

SINGAPORE, July 25, 2018 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection technology, and Mundipharma, today announced an exclusive partnership for the multinational healthcare organization to market and distribute PharmaJet’’s Tropis® and Stratis® needle-free devices across more than 120 markets worldwide.